Denis Chem LAB Ltd
BSE: DENISCHEM · Pharmaceuticals · sector
₹61.00BSE close 2026-10-26
Key numbers
Market cap₹85 cr
Price₹61.00
52w high / low₹95 / ₹56
P/E10.6xSector median 27.9x
P/B0.9xSector median 2.9x
Book value₹66.0
Dividend yield2.46%Sector median 0.48%
ROE9.0%Sector median 11.7%
ROCE12.5%Sector median 12.3%
OPM9.1%Sector median 14.0%
Debt / equity0.05xSector median 0.16x
EV/EBITDA3.6xSector median 18.6x
Interest cover15.7x
Current ratio2.70x
Sales growth 3y+4.2%Sector median +9.6%
Profit growth 3y+2.3%Sector median +13.3%
PEG4.61x
Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹29 cr vs borrowings ₹4 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 15.7x in the last 12 months.
- Other income was 26% of net profit in the last 12 months.
- Dividend paid in 4 of the last 5 financial years.
- Price ₹61.00 on 2026-10-26: -35.5% from the 52-week high, +8.7% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹172.20 · low ₹61.00
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 41 | 43 | 46 | 46 | 47 | 44 |
| EBITDA | 2 | 5 | 4 | 6 | 3 | 4 |
| OPM % | 5.0% | 11.1% | 9.2% | 13.2% | 5.4% | 8.7% |
| Other income | 1 | 0 | 1 | 0 | 1 | 0 |
| Net profit | 1 | 2 | 2 | 3 | 0 | 2 |
| EPS (₹) | 0.51 | 1.78 | 1.60 | 2.39 | 0.29 | 1.47 |
| Revenue YoY | +13.0% | +1.7% | ||||
| Profit YoY | -43.7% | -17.3% |
Standalone figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 137 | 161 | 168 | 173 | 182 | 182 |
| EBITDA | 14 | 19 | 21 | 16 | 18 | 17 |
| Net profit | 6 | 8 | 11 | 8 | 8 | 8 |
| EPS (₹) | 4.51 | 5.66 | 8.04 | 5.82 | 6.06 | 5.75 |
| Revenue growth | +17.8% | +4.3% | +3.3% | +4.9% | – | |
| Profit growth | +25.6% | +42.0% | -27.6% | +4.1% | – | |
| Dividend / share (₹) | – | 1.50 | 2.00 | 2.50 | 1.50 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +4.2% | – | – |
| Net profit | +2.3% | – | – |
| EPS | +2.3% | – | – |
| Share price | – | -37.7% (2y) | -33.8% |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 85 | 92 |
| Borrowings | 1 | 4 |
| Cash & equivalents | 26 | 29 |
| Total assets | 112 | 125 |
| Fixed assets | 39 | 37 |
| Capital work in progress | 0 | – |
| Investments | 0 | 0 |
| Receivables | 31 | 39 |
| Inventory | 10 | 11 |
| Payables | 21 | 22 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | 12 | 4 |
| Cash from investing | -8 | -5 |
| Cash from financing | -4 | 0 |
| Capex | 8 | 5 |
| Free cash flow | 4 | -1 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | 9.5% | 9.2% |
| ROCE % | 13.5% | 13.3% |
| Debtor days | 64 | 78 |
| Inventory days | 37 | 40 |
| Payable days | 81 | 81 |
| Cash conversion cycle (days) | 20 | 37 |
| Working capital days | 94 | 108 |
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| DENISCHEM | ₹85 cr | 10.6x | 0.9x | 9.0% | 12.5% | 9.1% | +4.2% | 2.46% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-09-18 | Dividend | Final Dividend Rs 2.5 |
| 2025-09-19 | Dividend | Final Dividend Rs 1.5 |
| 2024-09-19 | Dividend | Final Dividend Rs 2.5 |
| 2023-09-22 | Dividend | Final Dividend Rs 2.0 |
| 2022-09-20 | Dividend | Final Dividend Rs 1.5 |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | DENISCHEM |
| BSE code | 537536 |
| ISIN | INE051G01012 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-23 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.